Trial Profile

Pharmacokinetics of Single-dose Dolutegravir in HIV-seronegative Subjects With Severe Hepatic Impairment Compared to Matched Controls.

Status: Withdrawn prior to enrolment

Phase of Trial: Phase IV

Latest Information Update: 10 Feb 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dolutegravir (Primary)
Indications HIV infections; HIV-1 infections
Focus Pharmacokinetics
Acronyms POLO

Most Recent Events

07 Jun 2021 Status changed from recruiting to withdrawn prior to enrolment.
10 Sep 2020 Planned initiation date (estimated date for recruitment of the first subject) changed from 15 July 2020 to 20 Nov 2020.
10 Jul 2020 Planned End Date changed from 1 Dec 2019 to 31 Dec 2021.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com